For ophthalmic use only. Instill one drop into the conjunctival sac. If more than one topical ophthalmic drug is being used, they should be administered at least 5 minutes apart.

Brinzolamide inhibits carbonic anhydrase in the ciliary body of the eye. This enzyme is responsible for the formation of bicarbonate ions, which in turn leads to the production of aqueous humor. By inhibiting carbonic anhydrase, Brinzolamide decreases the rate of aqueous humor secretion, thereby lowering intraocular pressure.

• •Hypersensitivity to the active substance or to any of the excipients.
• •Known hypersensitivity to sulfonamides.
• •Severe renal impairment.
• •Hyperchloraemic acidosis.

Store at room temperature (15-25°C), protect from light, do not freeze

Systemic overdose is unlikely due to ocular administration. If swallowed, supportive measures are recommended. Electrolyte imbalance may occur.

Use only if the potential benefit justifies the potential risk to the fetus. Not known whether Brinzolamide is excreted in human milk. A risk to the suckling child cannot be excluded. Decision to discontinue breastfeeding or therapy should be made.